SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. (“Eastbourne”) announced today that it had filed with the Securities and Exchange Commission a detailed presentation for shareholders in connection with its solicitation of proxies in support of the election of three new directors to the 12 member Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin”) (NASDAQ: AMLN) at Amylin’s 2009 Annual Meeting of Shareholders. Eastbourne’s proposed nominees are Dr. Kathleen Behrens, Charles Fleischman and Jay Sherwood. Eastbourne currently owns approximately 12.5% of Amylin’s outstanding shares. In its definitive proxy statement filed earlier this week, Eastbourne also indicated it is seeking authority to vote for two of the nominees proposed by affiliates of Carl Icahn.
